VNDA NASDAQ
Vanda Pharmaceuticals Inc.
1W: -3.7%
1M: -22.0%
3M: -23.6%
YTD: -52.2%
1Y: -28.2%
3Y: -8.6%
5Y: -78.2%
$3.99
+0.05 (+1.27%)
After Hours: $3.92 (-0.07, -1.75%)
Weekly Expected Move ±5.0%
$4
$4
$4
$4
$4
Credit Risk of going bust: higher than 65% of companies Debt: 8.7% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.06 (down 99%), Vanda Pharmaceuticals Inc. would be worth roughly what it owes.
Total debt $22.8M against a stock market value of $238.2M.
Distance to default 3.79 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $11.4M (short-term plus half of long-term), stock volatility 78.5%; Altman Z'' -4.18. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.06 (down 99%), Vanda Pharmaceuticals Inc. would be worth roughly what it owes.
Total debt $22.8M against a stock market value of $238.2M.
Distance to default 3.79 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $11.4M (short-term plus half of long-term), stock volatility 78.5%; Altman Z'' -4.18. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
-0.90
Bearish
0 bullish
0 neutral
1 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (87)
Fortrea Holdings Inc. (FTRE) Earnings Expected to Grow: Should You Buy?
XENE's Depression Trial Setback: Is Its Pipeline Still Attractive?
Vanda puts anxiety drug program on hold after Phase III setback
At a glance: stocks gapping up premarket
Vanda posts late-stage trial win for HETLIOZ in DSWPD, setting up another label expansion
BlackRock Inc. Makes New Investment in Vanda Pharmaceuticals Inc. $VNDA
Connor Clark & Lunn Investment Management Ltd. Invests $1.32 Million in Vanda Pharmaceuticals Inc. $VNDA
NEREUS™ Sponsored No. 47 IndyCar Ready for Historic Freedom 250 Grand Prix in Washington, D.C.
Vanda (VNDA) Q2 2026 Earnings Call Transcript
4 Psoriasis Drug Stocks to Watch During Psoriasis Awareness Month 2026
Dimensional Fund Advisors LP Lowers Holdings in Vanda Pharmaceuticals Inc. $VNDA
Arrowstreet Capital Limited Partnership Buys New Position in Vanda Pharmaceuticals Inc. $VNDA
Vanda Pharmaceuticals Inc. Q2 2026 Earnings Call Summary
Vanda Pharmaceuticals (VNDA) Reports Q2 Loss, Lags Revenue Estimates
Vanda Pharmaceuticals Announces FDA Rare Pediatric Disease Designation for Investigational Therapy for Charcot-Marie-Tooth Disease Type 2S
Vanda targets $240M-$290M 2026 revenue as it introduces $10M-$30M NEREUS sales outlook
Vanda Pharmaceuticals Inc. Q1 2026 Earnings Call Summary
Vanda (VNDA) Q1 2026 Earnings Call Transcript
Vanda Pharmaceuticals (VNDA) Reports Q1 Loss, Lags Revenue Estimates
Earnings Scheduled For May 6, 2026
Wall Street Analysts Predict a 105.03% Upside in Vanda (VNDA): Here's What You Should Know
Vanda rises after hours on launch of tradipitant for motion sickness
Incyte (INCY) Beats Q1 Earnings and Revenue Estimates
Vanda Pharmaceuticals Appoints Dr. Charles Duncan to its Board of Directors
Vanda Pharmaceuticals (NASDAQ:VNDA) Stock Passes Above 200-Day Moving Average – Time to Sell?
AnaptysBio rises after completing First Tracks spinoff
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Given Average Recommendation of “Moderate Buy” by Brokerages
Vanda Pharmaceuticals Calls on FDA to Withdraw Proposal from FY 2027 Legislative Agenda That Would Extend Drug Review Timelines
Vanda Pharmaceuticals (NASDAQ:VNDA) Share Price Passes Above 200-Day Moving Average – Should You Sell?
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Short Interest Update
Vanda Pharmaceuticals (NASDAQ:VNDA) Share Price Passes Above 200-Day Moving Average – Here’s Why
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Receives Average Recommendation of “Moderate Buy” from Analysts
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Short Interest Up 25.3% in February
This Equinix Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Q1 Earnings Estimate for VNDA Issued By HC Wainwright
Vanda granted public hearing to review FDA denying Hetlioz for jet lag
Vanda Announces FDA Grants Landmark Hearing for HETLIOZ® in Jet Lag Disorder, the First Drug Approval Hearing in Over 40 Years
Vanda Pharmaceuticals (NASDAQ:VNDA) Share Price Passes Above Two Hundred Day Moving Average – Should You Sell?
Vanda Pharmaceuticals Breaks Through With FDA Approval, Decision Date For Skin Drug
Vanda skin disorder drug accepted for FDA review
Vanda Pharmaceuticals Breaks Through With FDA Approval, Decision Date For Skin Drug
Vanda Pharmaceuticals Announces FDA Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis
What's Going On With Vanda Pharma Stock Tuesday?
Vanda Pharmaceuticals: Soaring On Bysanti Approval, But You Shouldn't Feel Dizzy
Vanda Pharmaceuticals FDA Approval Dawns A New Era For Bipolar And Schizophrenia Treatment
Vanda Pharmaceuticals stock's explosive rally may be more hype than substance
Biggest stock movers Monday: NVO, VNDA, and more
Vanda Pharmaceuticals FDA Approval Dawns A New Era For Bipolar And Schizophrenia Treatment
Vanda surges as FDA approves Bysanti for bipolar disorder, schizophrenia
US FDA approves Vanda's psychiatric drug
Vanda Pharmaceuticals Announces FDA Approval of BYSANTI™ (milsaperidone) for the treatment of Bipolar I Disorder and Schizophrenia - A New Chemical Entity Opening New Horizons in Psychiatric Innovation
Vanda Pharmaceuticals Inc. (VNDA) Q4 2025 Earnings Call Transcript
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA
Vanda Pharmaceuticals (VNDA) Reports Q4 Loss, Lags Revenue Estimates
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results on February 11, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA
Vanda Pharmaceuticals Inc. (VNDA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Lost Money on Vanda Pharmaceuticals Inc. (VNDA)? Contact Levi & Korsinsky About Fraud Investigation
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDA
Vanda (VNDA) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Vanda and Exante Data Combine in Strategic Merger
Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ® Supplemental New Drug Application for Jet Lag Disorder
Vanda Pharmaceuticals (NASDAQ:VNDA) Reaches New 12-Month High – What’s Next?
S&P 500 Falls For Fourth Session But Records Gains In 2025: Investor Sentiment Declines, Fear & Greed Index Remains In 'Neutral Zone
Vanda's 2026 Catalyst Run With Nereus Launch And Bysanti PDUFA In Focus
What's Going On With Vanda Pharmaceuticals Stock Wednesday?
Vanda Pharma's (VNDA) NEREUS Approval Boosts Growth Prospects
Vanda Pharmaceuticals Shares Jump 30% on Motion Sickness Drug Approval
Vanda Jumps 21% After FDA Approves Motion Sickness Therapy
VNDA Obtains FDA Nod for Motion Sickness Drug, Stock Gains
US FDA approves Vanda Pharmaceuticals' motion sickness drug
Vanda Pharmaceuticals Announces FDA Approval of NEREUS™ (tradipitant) for the Prevention of Vomiting Induced by Motion: A Historic Scientific Milestone in the Prevention of Motion Sickness
Vanda Pharmaceuticals Stock Rallies on FDA Filing
Squarepoint Ops LLC Has $724,000 Position in Vanda Pharmaceuticals Inc. $VNDA
Vanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare Conference
FDA Lifts Partial Clinical Hold on Tradipitant for Motion Sickness
Should You Invest in This Under-the-Radar Weight Loss Stock?
FDA Fast-Tracks Vanda's Motion Sickness Drug Review After Leadership Shake-Up
Vanda Pharmaceuticals Provides Regulatory Update on Tradipitant for Motion Sickness
Vanda Pharmaceuticals: Commercial Execution Meets Pipeline Optionality
VNDA Stock Jumps on Upbeat Tradipitant Data Cutting GLP-1 Side Effects